Antigenic peptides deriving from urocortin 3 and uses thereof for the diagnosis and treatment of type 1 diabetes

Despite the notion that human CD8+ T cells are the final mediators of autoimmune ?- cell destruction in type 1 diabetes (T1D), none of their target epitopes has been demonstrated to be naturally processed and presented by ? cells. The inventors therefore performed an epitope discovery study combining HLA Class I peptidomics and transcriptomics strategies.
Inflammatory cytokines increased ?-cell peptide presentation in vitro, paralleling upregulation of HLA Class I expression. Peptide sources included known ?-cell antigens and several insulin granule proteins. Urocortin 3 was identified as a novel ?-cell antigen, which was processed into HLA-A2- and HLA-A3-restricted epitopes recognized by circulating naïve CD8+ T cells in type 1 diabetic and healthy donors. Accordingly, the present invention relates to antigenic peptides derived from urocortin-3 and uses thereof for the diagnosis and treatment of T1D.

Patent Application number: European Procedure (Patents) (EPA) - 16 Mars 2018 - 18 305 288.5
Inventors:
MALLONE Roberto,GONZALEZ-DUQUE Sergio,AFONSO Georgia,VINH Joëlle,VERDIER Yann,AZOURY Marie Eliane

Reference:

BIO17685-T1

Business Developper
contact
Aymeric Empereur
Business Developer
Rare disease: No
Second indication: No

You might also be interested in